

# New Zealand Economic Comment

## RBNZ cuts 25bp; further easing will be required

### Economics

#### New Zealand

#### RBNZ cuts OCR 25bp to 2.0%, as widely anticipated

With the release of its August Monetary Policy Statement (MPS), the RBNZ reduced the Official Cash Rate (OCR) by 25bp to 2.0%. The 25bp policy rate cut was in line with our expectation and that of economist polls, which put high odds on such an action. The market response (NZ dollar higher and bond sell-off) suggests that markets were pricing more of a risk that the RBNZ could cut 50bp on this occasion. We did not regard this as a serious option (nor did the RBNZ, it would appear).

#### Signals that 'further policy easing will be required'

In respect of forward guidance, the RBNZ made it clear that 'Our current projections and assumptions indicate that further policy easing will be required to ensure that future inflation settles near the middle of the target range' and that 'The Bank judges that monetary policy will need to be more stimulatory than projected in June'. The Bank's 90-day track shows rates reaching a low of 1.8% by Q2 next year, against a low of 2.1% projected by that quarter in the June MPS.

#### Most risks are to the downside for inflation and rates

While the RBNZ has upgraded growth forecasts over the full forecast horizon, the near-term inflation outlook has been reduced, largely on account of the higher currency. An expected depreciation in the NZ dollar relies on improving global conditions but the RBNZ observes that the downside risks to the global outlook remain 'substantial'. Both the 'higher exchange rate' and 'lower inflation expectations' scenarios suggest the OCR could (all else equal) fall as low as around 1% towards the end of next year.

#### Implications: We now expect the OCR to fall to 1.75% and stay there until 2018

We agree with the RBNZ's assessment that an additional OCR cut is likely to be required and (despite the timing implied by the 90-day projections) will probably happen at the 10 November MPS. We then expect that emerging capacity pressures, and ongoing housing market tensions, will keep the OCR on hold at 1.75% for an extended period, through the end of next year. The start of 'normalisation' we had pencilled in for mid-next year has been pushed out to the beginning of 2018.

#### Robin Clements

Economist

robin.clements@ubs.com

+64-3-358 9150

#### Scott Haslem

Economist

scott.haslem@ubs.com

+61-2-9324 3663

#### George Tharenou

Economist

george.tharenou@ubs.com

+61-2-9324 3520


#### Jim Xu

Associate Analyst

jim.xu@ubs.com

+61-2-9324 2665

Figure 1: 90-day rates



Source: RBNZ, UBS

## August 2016 Monetary Policy Statement

With the release of its August Monetary Policy Statement (MPS), the RBNZ reduced the Official Cash Rate (OCR) by 25bp to 2.0%, having left the OCR unchanged in June and April. This is the first OCR move since the March MPS, which was also a 25bp reduction. The 25bp policy rate cut was in line with our expectation and that of economist polls, which put high odds on such an action.

The market response (NZ dollar higher and bond sell-off) suggests that markets were pricing more of a risk that the RBNZ could cut 50bp on this occasion. We did not regard this as a serious option (nor did the RBNZ, it would appear), with 50bp moves generally reserved for situations where there is some form of 'emergency', requiring a rapid change in policy settings. Certainly, the RBNZ's 21 July Economic Update did not convey any sense of urgency that would have suggested that a 50bp move was being considered. Moreover, while markets may have thought a 50bp move was a necessary 'surprise' to budge the NZ dollar, we do not believe the RBNZ would use monetary policy in such a manner unless it was already justified by inflation-related factors.

**Figure 2: Key policy projections**

	2016 Q1	2017 Q1	2018 Q1	2019 Q1
CPI (q/q)	0.2	0.2	0.4	0.5
CPI (y/y)	0.4	1.1	1.7	2.1
90-Day Bank Bill	2.6	2.0	1.8	1.8
TWI	72.2	75.6	74.0	73.0

Source: Statistics NZ, RBNZ, UBS

In respect of forward guidance, the RBNZ made it clear that 'Our current projections and assumptions indicate that further policy easing will be required to ensure that future inflation settles near the middle of the target range' and that 'The Bank judges that monetary policy will need to be more stimulatory than projected in June'. The Bank's 90-day track shows rates reaching a low of 1.8% by Q2 next year, against a low of 2.1% projected by that quarter in the June MPS.


On the global front, there has been further deterioration and the RBNZ notes that, in addition to downward revisions to the global growth outlook, 'Global economic conditions are fragile' and 'Downside risks to the global growth outlook remain substantial'. However, much of the discussion on international developments concerns the situation where subdued, below potential, global growth has meant significant spare capacity and, in association with falls in commodity prices, low global inflation. In turn, this has led to further policy easing and historically low global interest rates, contributing to the attractiveness of NZ dollar assets.

As was highlighted in the RBNZ's 21 July update, the high exchange rate is making 'it difficult for the Bank to meet its inflation objective'. Since the June MPS, the TWI has appreciated about 4% and is currently over 6% above the TWI assumed for the current quarter in the June MPS. Accordingly, the RBNZ has lifted its assumed TWI path by around 6% but still assumes a near 4% depreciation over the forecast horizon, reflecting a gradual improvement in global economic conditions and a narrowing in interest rate differentials (presumably, US in particular).

The RBNZ states that 'A decline in the exchange rate is needed', which is not especially aggressive language but describes the exchange rate as 'elevated in comparison to the level of NZ's export commodity prices, interest rate differentials,

and relative economic activity' i.e. verging on the 'unjustified by economic fundamentals' terminology condition for intervention but not quite! The 'higher TWI' scenario (discussion of which has moved from the back of the document to the front policy assessment) has the TWI unchanged from 76 and, 'all else equal' the 90-day rate falling to near 1% by late 2017 (much the same as in the June MPS).

**Figure 3: CPI inflation**



Source: Statistics NZ, RBNZ, UBS

The 21 July RBNZ update said that the stronger NZ dollar implied that the 'outlook for inflation has weakened'. Indeed, the RBNZ's updated inflation forecasts show forecast CPI inflation 0.4 percentage points lower than in the June MPS for the March 2017 quarter (1.5% y/y to 1.1% y/y), although in part this is lower projected petrol/fuel prices in Q3, and for the March 2018 quarter (2.0% y/y to 1.6% y/y). The RBNZ has CPI inflation returning to near the mid-point of the target band by Q3 of 2018, three quarters later than projected in the June MPS. Inflation goes a little higher at the end of the projections (over 2% as opposed to under, previously), arguably on account of a stronger growth forecast on the back of more stimulatory monetary policy.

The RBNZ is projecting the economy to expand by 3.4% in each of the next two years (March year averages), up by 0.2 percentage points for 2017 and 0.4%pts for 2018 compared with the June MPS. While the Bank expects growth to moderate in the year to March 2019, the 2.6% average growth forecast is 0.5%pts higher than projected in the June MPS. The rate of potential growth is expected to remain near 2.7%, supported by strong growth in labour supply. The output gap is estimated to be currently around zero. As capacity pressure increases, annual non-tradables inflation is expected to rise throughout the projection. Over the medium term, tradables inflation is expected to increase gradually, in part due to the exchange rate depreciating from its current level.

**Figure 4: Economic Projections**

		2015	2016	2017	2018	2019
<b>CPI inflation</b>	y/y%	0.3	0.4	1.1	1.7	2.1
<b>Real GDP</b>	An Av%	3.6	2.5	3.4	3.4	2.6
<b>Unemployment Rate</b>	1Q, sa	5.4	5.2	4.8	4.4	4.5
<b>Gov't Operating Balance</b>	Jun Yr, % GDP	0.2	0.2	0.3	1.0	1.7
<b>Current Account</b>	% GDP	-3.4	-3.0	-3.2	-3.4	-3.0

Source: Statistics NZ, RBNZ

Domestic growth is expected to remain supported by strong inward migration, construction activity, tourism, and accommodative monetary policy. However, low dairy prices are seen depressing incomes in the dairy sector and reducing farm spending and investment. Construction activity is expected to be an important source of output growth and capacity pressure over the projection. The increase in residential investment is expected to be larger and more sustained than in the June MPS. This increase is underpinned by the existing housing shortage, strong population growth, high house prices, and low interest rates.

The RBNZ notes that short-term inflation expectations appear to have stabilised since March, while long-term expectations appear well anchored but there remains a risk of further declines in expectations stemming from persistent low inflation (the Bank now forecasts annual inflation to drop to 0.2% y/y in the current quarter). The RBNZ argues that a further sustained decline in inflation expectations would be concerning and would make it difficult to meet the inflation target. Thus, a key element in the rationale for further easing is that 'It is important to reduce the risk that long-term inflation expectations fall further and become unanchored from the target midpoint'.

The RBNZ suggests that house price inflation 'remains excessive' and has become more broad-based across the regions, adding to concerns about financial stability. There is a risk that the additional monetary stimulus will intensify house price inflation but the Bank points out that the recently proposed changes to macro-prudential policy should help to mitigate the risks to financial stability stemming from high house prices and rapid house price inflation.

### Valuation Method and Risk Statement

Risks of multi-asset investing include but are not limited to market risk, credit risk, interest rate risk, and foreign exchange risk. Correlations of returns among different asset classes may deviate from historical patterns. Geopolitical events and policy shocks pose risks that can reduce asset returns. Valuations may be adversely affected during times of high market volatility, thin liquidity, and economic dislocation.

## Required Disclosures

This report has been prepared by UBS New Zealand Ltd, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit [www.ubs.com/disclosures](http://www.ubs.com/disclosures). The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 11 August 2016 02:12 AM GMT.

**Analyst Certification:** Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

## Company Disclosures

---

### Issuer Name

**Commonwealth of Australia**<sup>2, 4, 7</sup>

**Dominion of New Zealand**<sup>2, 4, 7</sup>

---

2. UBS AG, its affiliates or subsidiaries has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
4. Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking services from this company/entity or one of its affiliates.
7. Within the past 12 months, UBS Securities LLC and/or its affiliates have received compensation for products and services other than investment banking services from this company/entity.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.

## Global Disclaimer

This document has been prepared by UBS New Zealand Ltd, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

Global Research is provided to our clients through UBS Neo and, in certain instances, UBS.com (each a "System"). It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

All Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, your use shall be subject to this Global Research Disclaimer and to UBS's Terms of Use/Disclaimer (<http://www.ubs.com/global/en/legalinfo2/disclaimer.html>). By accessing and/or using Global Research in this manner, you are indicating that you have read and agree to be bound by our Terms of Use/Disclaimer. In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<http://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<http://www.ubs.com/global/en/homepage/cookies/cookie-management.html>).

**If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, transfer to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.**

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this document ("the Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

This document and the Information are produced by UBS as part of its research function and are provided to you solely for general background information. UBS has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. In no circumstances may this document or any of the Information be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit [www.ubs.com/disclosures](http://www.ubs.com/disclosures).

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on NEO. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

**United Kingdom and the rest of Europe:** Except as otherwise specified herein, this material is distributed by UBS Limited to persons who are eligible counterparties or professional clients. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:**

Distributed by UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Limited and distributed by UBS Limited and UBS Limited, Italy Branch. Where an analyst of UBS Limited, Italy Branch has contributed to this document, the document is also deemed to have been prepared by UBS Limited, Italy Branch. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Israel:** This material is distributed by UBS Limited. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS Limited and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS Limited is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS Limited and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only to persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons. **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **Dubai:** The information distributed by UBS AG Dubai Branch is intended for Professional Clients only and is not for further distribution within the United Arab Emirates. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a "non-US affiliate") to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Mexico:** This report has been distributed and prepared by UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is an affiliate of UBS AG. This document is intended for distribution to institutional or sophisticated investors only. Research reports only reflect the views of the analysts responsible for the reports. Analysts do not receive any compensation from persons or entities different from UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, or different from entities belonging to the same financial group or business group of such. For Spanish translations of applicable disclosures, please see [www.ubs.com/disclosures](http://www.ubs.com/disclosures). **Brazil:** Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be: (i) financial institutions, (ii) insurance firms and investment capital companies, (iii) supplementary pension entities, (iv) entities that hold financial investments higher than R\$300,000.00 and that confirm the status of qualified investors in written, (v) investment funds, (vi) securities portfolio managers and securities consultants duly authorized by Comissão de Valores Mobiliários (CVM), regarding their own investments, and (vii) social security systems created by the Federal Government, States, and Municipalities. **Hong Kong:** Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch. **Singapore:** Distributed by UBS Securities Pte. Ltd. [MCI (P) 018/09/2015 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Clients of UBS AG: Distributed by UBS AG (Holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: [www.ubs.com/ecs-research-fsg](http://www.ubs.com/ecs-research-fsg). **New Zealand:** Distributed by UBS New Zealand Ltd. The information and recommendations in this publication are provided for general information purposes only. To the extent that any such information or recommendations constitute financial advice, they do not take into account any person's particular financial situation or goals. We recommend that recipients seek advice specific to their circumstances from their financial advisor. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMS/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. **India:** Distributed by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, NSE (Currency Derivatives Segment) INE230951431, BSE (Capital Market Segment) INB010951437; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: [http://www.ubs.com/global/en/about\\_ubs/investor\\_relations/annualreporting.html](http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html)

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2016. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

